Restless legs syndrome due to interferon-α

Movement Disorders

Volumn 19, Issue 6, 2004, Pages 730-731

  LaRochelle, Jeffrey S ^a   Karp, Barbara I ^b  

^a WILFORD HALL MEDICAL CENTER   (United States)

^b NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

Author keywords

Interferon ; Movement Disorder; Restless legs syndrome

Indexed keywords

ALPHA INTERFERON; BROMOCRIPTINE; CODEINE; PEGINTERFERON; RIBAVIRIN;

ADULT; ARTICLE; CASE REPORT; CLINICAL TRIAL; DRUG WITHDRAWAL; ELECTROMYOGRAM; HEPATITIS C; HUMAN; LEG PAIN; MALE; MOTOR DYSFUNCTION; NEUROLOGIC EXAMINATION; NEUTROPENIA; PARESTHESIA; PRIORITY JOURNAL; PROVOCATION TEST; RESTLESS LEGS SYNDROME; SLEEP DISORDER; SYMPTOMATOLOGY;

ANTIVIRAL AGENTS; BIOPSY; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; LIVER; MALE; MIDDLE AGED; RESTLESS LEGS SYNDROME; SEVERITY OF ILLNESS INDEX;

EID: 4444265717     PISSN: 08853185     EISSN: None     Source Type: Journal    
DOI: 10.1002/mds.20049     Document Type: Article

References (16)

1. Shad JA, McHutchinson JG. Current and future therapies of hepatitis C. Clin Liver Dis 2001;5:335-339.
2. Moulignier A, Allo S, Zittoun R, Gout O. Recombinant interferon-alpha-induced chorea and frontal subcortical dementia. Neurology 2002;58:328-330.
3. Renault PF, Hoofnagle JH, Park Y, Mullen KD, Peters M, Jones DB, et al. Psychiatric complications of long-term interferon alfa therapy. Arch Intern Med 1987;147:1577-1580.
4. Sunami M, Nishikawa T, Yorogi A, Shimoda M. Intravenous administration of levodopa ameliorated a refractory akathisia case induced by interferon-alpha. Clin Neuropharmacol 2000;23:59-61.
5. Horikawa N, Yamazaki T, Sagawa M, Nagata T. A case of akathisia during interferon-alpha therapy for chronic hepatitis type C. Gen Hosp Psychiatry 1999;21:134-135.
6. Meyers CA, Scheibel RS, Forman AD. Persistent neurotoxicity of systemically administered interferon-alpha. Neurology 1991;41: 672-676.
7. Walters AS. Toward a better definition of the restles legs syndrome. The International Restless Legs Syndrome Study Group. Mov Disord 1995;10:634-642.
8. Ioannou GN, Tung BY, Kowdley KV. Iron in hepatitis C: villain or innocent bystander? Semin Gastrointest Dis 2002;13:95-108.
9. Tembl JI, Ferrer JM, Sevilla MT, Lago A, Mayordomo F, Vilchez JJ. Neurologic complications associated with hepatitis C virus infection. Neurology 1999;53:861-864.
10. Ruottinen HM, Partinen M, Hublin C, Bergman J, Haaparanta M, Solin O, et al. An FDOPA PET study in patients with periodic limb movement disorder and restless legs syndrome. Neurology 2000; 54:502-504.
11. 11C-raclopride PET studies. Neurology 1999;52:932-937.
12. Shuto H, Kataoka Y, Horikawa T, Fujihara N, Oishi R. Repeated interferon-alpha administration inhibits dopaminergic neural activity in the mouse brain. Brain Res 1997;747:348-351.
13. Dafny N. Is interferon-alpha a neuromodulator? Brain Res Brain Res Rev 1998;26:1-15.
14. Ho BT, Lu JG, Huo YY, Fan SH, Meyers CA, Tansey LW, et al. The opioid mechanism of interferon-alpha action. Anticancer Drugs 1994;5:90-94.
15. Prummel MF, Laurberg P. Interferon-alpha and autoimmune thyroid disease. Thyroid 2003;13:547-551.
16. Fabris P, Floreani A, Tositti G, Vergani D, De Lalla F, Betterle C. Type 1 diabetes mellitus in patients with chronic hepatitis C before and after interferon therapy. Aliment Pharmacol Ther 2003;18:549-558.